[Malvern, PA, October 18, 2023] — LifeSensors Inc., a biotech company targeting the ubiquitin proteasome system for drug discovery and diagnostic markers, has received funding from the National Institute on Aging and National Institute of General Medicine. The funding, to the tune of $5.53 million, provides for the development of PROTAC drug discovery technologies. PROTACs […]
MALVERN, Pa., SEP 21, 2023 — LifeSensors Inc., a Biotech and Drug Discovery Company focused on PROTAC, molecular glue drug discovery and neurodegeneration diagnostics has been invited to speak at the 21st annual Discovery on Target 2023. Dr. Karteek Kadimisetty, LifeSensors’ Director of Research and Development will be presenting new information, and answering questions regarding PROTACs, […]
MALVERN, PA., May 30, 2023 — LifeSensors Inc., a Biotech and Drug Discovery Company focused on PROTACs, molecular glues, and neurodegeneration diagnostics will disclose direct methods to detect PROTAC & molecular glue mediated ubiquitination drug targets at BIO this year in Boston, MA, June 5-8, 2023. Current methods of PROTAC & Molecular Glue discovery are time consuming, […]
By: Abdul Haseeb, Ph.D. Drugging the Undruggable Tremendous progress in genomics, transcriptomics and proteomics has led to the discovery of thousands of new drivers of disease, but drug discovery is still catching up to these new potential drug targets because most of these new players are intractable to traditional pharmacological targeting. Traditional small molecule […]
